DOT World

Executive Summary

DOT World is a Japanese contract research organization (CRO) providing end-to-end clinical trial support for pharmaceuticals, medical devices, and Software as a Medical Device (SaMD). Founded in 2006 and based in Tokyo, the company specializes in investigator-initiated trials and serves venture companies, with particular expertise in rare diseases and digital health. By offering services from trial planning to regulatory submission, DOT World positions itself as a key partner for emerging biotech and medical device firms navigating Japan's evolving regulatory landscape. With a team of 50-200 employees, the company has built a reputation for supporting complex, technology-driven studies, leveraging Japan's growing emphasis on digital health innovation and rare disease treatments. The company's focus on SaMD and digital health aligns with Japan's regulatory push to streamline approvals for software-based therapies. As a private platform-stage entity, DOT World is poised to benefit from increased outsourcing by pharmaceutical and device companies seeking specialized CRO support. While its revenue and valuation are not publicly disclosed, its niche expertise in investigator-initiated trials and venture-backed projects suggests a stable, growth-oriented business model. The company's longevity since 2006 and established presence in Japan's competitive CRO market underscore its resilience and potential for capturing a larger share of the expanding clinical research outsourcing landscape in Asia.

Upcoming Catalysts (preview)

• Q3 2026Japan PMDA SaMD Approval Acceleration80% success
• Q4 2026Strategic Partnership with a Global Biotech60% success
• Q3 2026Expansion of Rare Disease Trial Portfolio75% success